Comparing Haemonetics (NYSE:HAE) & KORU Medical Systems (NASDAQ:KRMD)

KORU Medical Systems (NASDAQ:KRMD – Get Rating) and Haemonetics (NYSE:HAE – Get Rating) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their risk, profitability, earnings, analyst recommendations, institutional ownership, dividends and valuation.

Institutional & Insider Ownership

36.1% of KORU Medical Systems shares are held by institutional investors. 34.0% of KORU Medical Systems shares are held by insiders. Comparatively, 1.7% of Haemonetics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Profitability

This table compares KORU Medical Systems and Haemonetics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
KORU Medical Systems	-31.05%	-24.21%	-18.59%
Haemonetics	8.48%	19.84%	8.08%

Risk & Volatility

KORU Medical Systems has a beta of 0.42, suggesting that its share price is 58% less volatile than the S&P 500. Comparatively, Haemonetics has a beta of 0.43, suggesting that its share price is 57% less volatile than the S&P 500.

Analyst Recommendations

This is a summary of current recommendations and price targets for KORU Medical Systems and Haemonetics, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
KORU Medical Systems	0	0	3	0	3.00
Haemonetics	0	2	4	0	2.67

KORU Medical Systems presently has a consensus price target of $4.17, indicating a potential upside of 10.23%. Haemonetics has a consensus price target of $101.00, indicating a potential upside of 31.84%. Given Haemonetics’ higher probable upside, analysts clearly believe Haemonetics is more favorable than KORU Medical Systems.

Earnings & Valuation

This table compares KORU Medical Systems and Haemonetics’ revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
KORU Medical Systems	$27.90 million	6.17	-$8.66 million	($0.20)	-18.90
Haemonetics	$993.20 million	3.89	$43.38 million	$1.85	41.41

Haemonetics has higher revenue and earnings than KORU Medical Systems. KORU Medical Systems is trading at a lower price-to-earnings ratio than Haemonetics, indicating that it is currently the more affordable of the two stocks.

Summary

Haemonetics beats KORU Medical Systems on 10 of the 14 factors compared between the two stocks.

About KORU Medical Systems

(Get Rating)

KORU Medical Systems, Inc. engages in the design, manufacture, and market of proprietary medical devices. Its product portfolio includes FREEDOM60, FreedomEdge syringe drivers, Precision Flow Rate Tubing, and HIgH-Flo Subcutaneous Safety Needle Sets. The company was founded by Andrew I. Sealfon and Adrian W. Zorgniotti on March 24, 1980 and is headquartered in Mahwah, NJ.

About Haemonetics

(Get Rating)

Haemonetics Corp. is a global healthcare company, which engages in the development and distribution of hematology products and solutions. It operates through the following segments: Plasma, Blood Center, Hospital, and Corporate. The Plasma segment offers automated plasma collection and donor management software systems. The Blood Center segment provides solutions for donor collection centers’ ability to acquire blood, filter blood, and separate blood components. The Hospital segment includes hemostasis management, cell salvage, and transfusion management services that help decision makers in hospitals optimize blood acquisition, storage, and usage in critical settings. The company was founded by Allen Latham, Jr. in 1971 and is headquartered in Boston, MA.